Decibel Cannabis Past Earnings Performance
Past criteria checks 0/6
Decibel Cannabis has been growing earnings at an average annual rate of 17.8%, while the Pharmaceuticals industry saw earnings growing at 31.5% annually. Revenues have been growing at an average rate of 52.8% per year.
Key information
17.8%
Earnings growth rate
50.8%
EPS growth rate
| Pharmaceuticals Industry Growth | 23.1% |
| Revenue growth rate | 52.8% |
| Return on equity | -3.8% |
| Net Margin | -1.5% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Sentiment Still Eluding Decibel Cannabis Company Inc. (CVE:DB)
Mar 06
Here's Why Decibel Cannabis (CVE:DB) Is Weighed Down By Its Debt Load
Jan 10We Think Decibel Cannabis (CVE:DB) Is Taking Some Risk With Its Debt
Sep 28Cautious Investors Not Rewarding Decibel Cannabis Company Inc.'s (CVE:DB) Performance Completely
Jul 15Is Decibel Cannabis (CVE:DB) Using Debt Sensibly?
May 17Decibel Cannabis (CVE:DB) Has Debt But No Earnings; Should You Worry?
Nov 11Decibel Cannabis (CVE:DB) Use Of Debt Could Be Considered Risky
Jul 22Does Decibel Cannabis (CVE:DB) Have A Healthy Balance Sheet?
Nov 24Here's Why Decibel Cannabis (CVE:DB) Has A Meaningful Debt Burden
Aug 21Would Decibel Cannabis (CVE:DB) Be Better Off With Less Debt?
Apr 16Is Decibel Cannabis (CVE:DB) A Risky Investment?
Dec 28
Revenue & Expenses BreakdownBeta
How Decibel Cannabis makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 116 | -2 | 37 | 0 |
| 30 Sep 23 | 114 | -4 | 31 | 0 |
| 30 Jun 23 | 102 | 1 | 28 | 0 |
| 31 Mar 23 | 90 | -1 | 26 | 0 |
| 31 Dec 22 | 79 | -4 | 23 | 0 |
| 30 Sep 22 | 68 | -1 | 21 | 0 |
| 30 Jun 22 | 63 | -7 | 20 | 0 |
| 31 Mar 22 | 56 | -5 | 20 | 0 |
| 31 Dec 21 | 52 | 2 | 18 | 0 |
| 30 Sep 21 | 50 | -1 | 17 | 0 |
| 30 Jun 21 | 44 | -1 | 17 | 0 |
| 31 Mar 21 | 38 | -3 | 14 | 0 |
| 31 Dec 20 | 30 | -9 | 15 | 0 |
| 30 Sep 20 | 20 | -14 | 13 | 0 |
| 30 Jun 20 | 15 | -13 | 11 | 0 |
| 31 Mar 20 | 11 | -9 | 9 | 0 |
| 31 Dec 19 | 6 | -7 | 5 | 0 |
| 30 Sep 19 | 5 | -1 | 3 | 0 |
| 30 Jun 19 | 2 | -1 | 2 | 0 |
| 31 Mar 19 | 1 | -3 | 2 | 0 |
| 31 Dec 18 | 0 | -3 | 2 | 0 |
Quality Earnings: DB is currently unprofitable.
Growing Profit Margin: DB is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: DB is unprofitable, but has reduced losses over the past 5 years at a rate of 17.8% per year.
Accelerating Growth: Unable to compare DB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: DB is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (22%).
Return on Equity
High ROE: DB has a negative Return on Equity (-3.83%), as it is currently unprofitable.